Denali Therapeutics Inc. (NASDAQ:DNLI) Given Average Rating of “Moderate Buy” by Brokerages

Shares of Denali Therapeutics Inc. (NASDAQ:DNLI) have earned an average rating of “Moderate Buy” from the fourteen ratings firms that are currently covering the company, Marketbeat.com reports. Two analysts have rated the stock with a hold recommendation, eleven have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year price target among brokers that have covered the stock in the last year is $38.00.

Several analysts have recently weighed in on the company. The Goldman Sachs Group lowered their target price on Denali Therapeutics from $45.00 to $40.00 and set a “buy” rating for the company in a research note on Tuesday, January 28th. Stifel Nicolaus upgraded Denali Therapeutics from a “hold” rating to a “buy” rating and set a $37.00 target price for the company in a research note on Monday, December 16th. William Blair restated an “outperform” rating on shares of Denali Therapeutics in a research note on Wednesday, January 15th. JPMorgan Chase & Co. lowered their target price on Denali Therapeutics from $28.00 to $24.00 and set an “overweight” rating for the company in a research note on Tuesday, January 7th. Finally, HC Wainwright decreased their price target on Denali Therapeutics from $90.00 to $87.00 and set a “buy” rating for the company in a research note on Tuesday, January 7th.

Denali Therapeutics Trading Down 6.2 %

Shares of NASDAQ DNLI opened at $20.88 on Tuesday. Denali Therapeutics has a 12-month low of $14.56 and a 12-month high of $33.33. The company has a market cap of $3.01 billion, a P/E ratio of -7.57 and a beta of 1.43. The stock has a fifty day moving average price of $22.10 and a 200 day moving average price of $24.82.

Insider Activity

In other news, CEO Ryan J. Watts sold 29,266 shares of the firm’s stock in a transaction that occurred on Monday, January 6th. The shares were sold at an average price of $20.22, for a total transaction of $591,758.52. Following the completion of the sale, the chief executive officer now owns 260,721 shares of the company’s stock, valued at approximately $5,271,778.62. This trade represents a 10.09 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Steve E. Krognes sold 3,339 shares of the firm’s stock in a transaction that occurred on Tuesday, January 7th. The stock was sold at an average price of $20.81, for a total transaction of $69,484.59. Following the sale, the director now directly owns 25,757 shares of the company’s stock, valued at approximately $536,003.17. The trade was a 11.48 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 47,940 shares of company stock valued at $973,442. Insiders own 7.90% of the company’s stock.

Hedge Funds Weigh In On Denali Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the business. CWM LLC boosted its stake in Denali Therapeutics by 43.6% in the third quarter. CWM LLC now owns 2,153 shares of the company’s stock valued at $63,000 after acquiring an additional 654 shares during the last quarter. Quest Partners LLC bought a new position in shares of Denali Therapeutics during the third quarter worth $73,000. PNC Financial Services Group Inc. boosted its position in shares of Denali Therapeutics by 30.5% during the fourth quarter. PNC Financial Services Group Inc. now owns 3,790 shares of the company’s stock worth $77,000 after purchasing an additional 885 shares in the last quarter. Assetmark Inc. boosted its position in shares of Denali Therapeutics by 18.0% during the third quarter. Assetmark Inc. now owns 3,808 shares of the company’s stock worth $111,000 after purchasing an additional 580 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. boosted its position in shares of Denali Therapeutics by 21.6% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,178 shares of the company’s stock worth $152,000 after purchasing an additional 920 shares in the last quarter. 92.92% of the stock is owned by institutional investors.

About Denali Therapeutics

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.